Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.93 billion, has been navigating a complex market landscape with a mix ...

Teva delivered 3.4% revenue growth and $0.78 in adjusted EPS during the third quarter, beating consensus estimates by a low-single-digit and midteens percentage, respectively. The market reacted very ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...

Access to innovative medicines remains a critical issue in healthcare. Teva Pharmaceuticals is tackling this challenge head-on, driving scientific innovation to deliver high-quality medicines that ...

YARAL Pharma Inc. (Parsippany, NJ) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. Committed to advancing healthcare through high-quality ...

Glycerol phenylbutyrate oral liquid is indicated for the chronic management of patients with urea cycle disorders. Sims added, "It expands access for patients and providers, and reinforces our ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...